[1] Munch-Petersen B, Cloos L, Jensen HK, et al. Humanthymidinekinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul, 1995, 35(2):69-89.
[2] Boothman DA, Davis TW, Sahijdak WM. Enhanced expressionof thymidine kinase in human cells following ionizingradiation. Int J Radiat Oncol Biol Phys. 1994, 30(2):391-398.
[3] Sundseth R, Joyner SS, Moore JT, et al. The anti-human-immunodeficiency virus agent 3'-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Antimicrob Agents Chemother, 1996, 40(2):331-335.
[4] Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptakeas a measure of thymidine kinase-lactivity in A549 carcinoma cells. J Nucl Med, 2002, 43(9):1210-1217.
[5] Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3'deoxy-3-[18F]fluorothymidine ([18F] FLT)as a proliferation ima-ging tracer inhumans:correlation of [18F]FLT uptake by positron emissiontomography with Ki-67 immunohistochemistry and flow cytometIy in human lung tumors. Clin Cancer Res, 2002, 8(11):3315-3323.
[6] Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracictumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest, 2006, 129(2):393-401.
[7] Cole PD, Smith AK, Kamen BA. Osteosarcoma cells, resistantto methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs. Cancer Chemother Pharmacol, 2002,50(2):111-116.
[8] Buck AK, Schirrmeister H, Hetzel M, et al. 3-deoxy-3-[18F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res, 2002,62(12):3331-3334.
[9] Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation inbrain tumors with ^sup 18F-FLT PET:Comparison with 18F-FDG. J Nucl Med, 2005, 46(6):945-952.
[10] Nitzsche EU, Walter M, Schirp U, et al. Combined PET maging of proliferation and glycolysis forfollow up of brachytherapy in brain tumors. In:SNM 50th annual meeting. J Nucl Med, 2003, 44(7):24N-26N.
[11] Cerfolio RJ, Ojha B, Bryant AS, et al. The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg,2003, 76(3):861-866.
[12] Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET:18F-FLT versus 18F-FDG. J Nucl Med, 2003,44(9):1426-1431.
[13] Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with 18F-FLT and positron emission tomography. Nat Med,1998, 4(11):1334-1336.
[14] Silverman DH, Pio BS, Satyamurthy N, et al. Monitoring effects of breast cancer chemotherapy with fluorodeoxyglucose and fluoro-Lthymidine. J Nucl Med, 2002, 43(6):308-311.
[15] Pio BS, Park CK, Satyamurthy N, et al. Monitoring early and long-term effects of breast cancer chemotherapy with fluorodeoxyglucose and fluoro-L-thymidine. In:ASCO Conference, 2003.
[16] Buck AK, Pitterle K, Schirrmeister H, et al.[18F] FLT positron emission tomography forimaging non-Hodgkin's lymphoma and assessment of proliferative activity. J Nucl Med, 2003, 44(2):188-189.
[17] Cobben DC, Elsinga PH, Suurmeijer A J, et al. Detection and grading of soft tissue sarcomas ofthe extremities with 18F-3'-fluoro-3'-deoxy-L-thymidine. Clin Cancer Res, 2004, 10(5):1685-1690.
[18] Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev, 2004, 30(1):83-101.
[19] Ham SJ, van der Graaf WT, Pras E, et al. Soft tissue sarcoma of the extremities:A multimodality diagnostic and therapeutic approach. Cancer Treat Rev, 1998, 24(6):373-391.
[20] Dittmann H, McBride W, Stout D, et al. Post-irradiation temporal changes in glucose metabolismand cell proliferation in implanted murine tumors as measuredby FDG and FLT PET. J Nucl Med,2002, 43(1):25.
[21] Barthel H, Cleij MC, Collingride DR, et al. 18F-3'-Fluoro-3'-Deoxy-LThymldine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with PET. Cancer Res, 2003,63(13):3791-3798.
[22] Seitz U, Wagner M, Neumaier B, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'[18F]fluoro-3'-deoxythymidine ([18F] FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging, 2002, 29(9):1174-1181.